Outsourcing in Clinical Trials Europe 201421-22 May 2014, Brussels, Belgium
The OCT team would like to thank you for making the 2013 event such a huge success.
Earlier this year 250 industry professionals attended OCT Europe to learn from case-study based presentations, network with their peers, discover new solutions and services and find answers to all of their clinical outsourcing challenges.
Covering all aspects of clinical outsourcing from informed sourcing and efficient contract negotiation through to effective management, monitoring and communication techniques, this year’s agenda boasted presentations, case studies, panel discussions and roundtables all presented and facilitated by a high calibre speaking faculty from across Europe.
The Outsourcing Clinical Trial series is growing every year. View the full list of upcoming events to make sure you don’t miss any news. The list of websites will be updated as soon as new events are live so check back regularly
We are always happy to see photos taken at our events! If you have any you would like to submit, please email firstname.lastname@example.org The Arena Team
Contract Research Organization, Clinovo tells us about their experience and takeaways from Outsourcing in Clinical Trials Southern California.
Primary delegates for this event are those with responsibility for clinical outsourcing decisions and strategy within pharmaceutical, biotechnology, and virtual companies across Europe:CEOCMOCSOCFO
Outsourcing in Clinical Trials East Coast boasts a fantastic exhibition of outsourcing service providers and industry specialists. Our exhibition area is already filling up due to the fantastic event which took place at earlier this year.
Our production team will soon begin research to develop the 2014 agenda. Catering both to small to mid-sized biotech and pharma as well as the larger companies, this 2014 event will include a stream which offers content relevant to the company types separately.
US-based Sunesis Pharmaceuticals has started an investigator-sponsored Phase I/II trial of vosaroxin in combination with azacitidine for the treatment of patients with myelodysplastic syndrome (MDS).
US-based biopharmaceutical firm CytRx has released positive top-line efficacy results from a Phase IIb clinical trial, which evaluated the efficacy and safety of aldoxorubicin compared to doxorubicin in patients with first-line metastatic, locally ad…
Sunovion Pharmaceuticals has released results from a pooled analysis of three Phase III randomised, placebo-controlled trials (Studies 301, 302 and 304) assessing the safety and efficacy of once-daily Aptiom (eslicarbazepine acetate) as adjunctive tr…
US-based Verastem has started an open-label, dose escalation and schedule finding Phase I trial of a dual mTORC1/2 and PI3K inhibitor 'VS-5584' for treatment of patients with advanced solid tumours or lymphoma.
US-based biopharmaceutical firm Portola Pharmaceuticals has released additional results of a Phase II proof-of-concept trial of its investigational Factor Xa inhibitor antidote 'andexanet alfa (PRT4445)', in healthy volunteers who were administered t…